SCHEDULE 13D/A: RiverVest Investor Group Reduces Stake in OnKure Therapeutics Below 5% Threshold
Schedule 13D Amendment
A group of investment entities and individuals associated with RiverVest Venture Funds has reported ceasing beneficial ownership of more than 5% of OnKure Therapeutics, Inc.'s common stock.
Summary
- This Schedule 13D Amendment No. 2 reports a change in beneficial ownership of OnKure Therapeutics, Inc. (Issuer) common stock by a group of reporting persons associated with RiverVest Venture Funds.
- The reporting persons, including various RiverVest Venture Funds and their general partners, along with individuals John P. McKearn, Ph.D., Jay Schmelter, Thomas C. Melzer, and Niall O'Donnell, Ph.D., collectively ceased to own more than five percent of the Issuer's outstanding Common Stock.
- The event triggering this filing occurred on January 16, 2025.
- As of the filing, the aggregate beneficial ownership for the group, as represented by the highest individual reporting person (John P. McKearn, Ph.D. and Jay Schmelter), is 196,198 shares, representing 1.55% of the Issuer's common stock.
- The percentage of ownership is based on 12,652,890 shares of common stock outstanding as of November 4, 2024, as reported in OnKure Therapeutics' Form 10-Q filed on November 7, 2024.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative as a significant investor group reducing its stake below the 5% threshold can be interpreted by the market as a loss of confidence or a strategic exit, even though no specific reasons are provided in the filing.
Negatives
- A significant investor group, RiverVest Venture Funds and associated individuals, has reduced its beneficial ownership in OnKure Therapeutics, Inc. to below the 5% threshold, indicating a decrease in their stake.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding OnKure Therapeutics' future operations or financial performance.
Industry Context
This filing is a routine disclosure of a change in significant beneficial ownership by an investment group in a publicly traded company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: May perceive the reduction in a significant investor's stake as a negative signal, potentially impacting investor confidence and share price.
Key Dates
| Date | Description |
|---|---|
| 2024-11-04 | Date as of which 12,652,890 shares of OnKure Therapeutics' common stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2024-11-07 | Date OnKure Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the SEC, reporting outstanding shares. |
| 2025-01-16 | Date the reporting persons ceased to own more than five percent of OnKure Therapeutics' outstanding Common Stock, triggering this filing. |
| 2025-01-21 | Date the Schedule 13D Amendment No. 2 was signed by the reporting persons. |
Keywords
OnKure Therapeutics, RiverVest Venture Funds, SEC Filing, Schedule 13D, Beneficial Ownership, Stake Reduction, Investment Funds, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.